/
         
Home > News > Scientific news
 

Scientific news
Untitled Document
 
2008-05-09 - Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer: EORTC study 40015
Latest from Annals of Oncology, May 2008
2008-05-08 - Presence of CMV in brain tumors made the virus a useful target for immune-based therapy
Highlights from American Association of Neurological Surgeons, 26 April-1 May 2008, Chicago, USA
2008-05-07 - News from EMEA Committee for Medicinal Products for Human Use
Revised positive opinion for lapatinib
2008-05-06 - Weekly Paclitxel in the Adjuvant Treatment of Breast Cancer
Below the results of large study published in The New England Journal of Medicine
2008-05-05 - How the social environment can make people vulnerable to cancer
Researchers explore the link between the stress caused by social isolation and aggressive cancer types
2008-05-02 - Accessibility to targeted oncology drugs in Slovenia and selected European countries
Below the European Journal of Cancer
2008-04-30 - Researchers detailed how cellular strategies and new vaccines are changing the cancer treatment landscape
Highlights from 2008 Annual Meeting of the American Association for Cancer Research, April 12 - 16, San Diego, USA
2008-04-29 - Spotlight on the European Breast Cancer Conference 6
15-19 April, 2008, Berlin, Germany
2008-04-28 - Chemotherapy not responsible for cognitive disorders in breast cancer patients
From American Academy of Neurology Congress, Chicago, 12-19 April 2008
2008-04-27 - A crucial moment in lung cancer
Closing of the 1st European Lung Cancer Conference
2008-04-25 - Therapies delivered by "trojan" peptides and through the use of nanotechnology may enhance the effectiveness of cancer treatment
2008 Annual Meeting of the American Association for Cancer Research, April 12 - 16, San Diego, USA
2008-04-25 - Cancer immunotherapy shows long-term promise in lung cancer
Immunotherapy reduces relapse risk without the side-effects of chemotherapy
2008-04-25 - Viruses may play a role in lung cancer development
Preliminary findings suggest measles virus and human papilloma virus may be involved
2008-04-25 - Mutation database helps personalized treatment of lung cancer
An online compendium matches EGFR mutations with clinical outcomes
2008-04-25 - New genetic techniques to combat lung cancer
A highly accurate diagnostic assay for squamous cell carcinoma A three-gene prognostic classifier for early non-small-cell lung cancer Gene expression profile reveals mechanisms of squamous cell carcinogenesis
2008-04-25 - Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
A clinical trial evaluating the benefit of adding the drug sorafenib to the combination of carboplatin/paclitaxel chemotherapy for lung cancer patients has been stopped based on results from an interim analysis, after an independent data monitoring committee concluded that the study would not meet its primary endpoint of improved overall survival.
2008-04-24 - Stockholm declaration to get major cancer centers across Europe working together, creating a platform for translational research
The declaration followed a meeting where the results of the Eurocanplus project were discussed
2008-04-23 - Data on new biomarkers that can predict response to treatments for breast cancer, kidney and non-small cell lung cancer
2008 Annual Meeting of the American Association for Cancer Research, April 12 - 16, San Diego, USA
2008-04-22 - Chemotherapy-induced Anemia Increases Risk of Local Breast Cancer Recurrence
From Austrian Breast and Colorectal Cancer Study Group
2008-04-21 - Highlights from 2008 Annual Meeting of the American Association for Cancer Research, April 12 - 16, San Diego, USA
New drug compounds, and old ones put to new use showed promise and progress against basal cell, brain, rectal, ovarian and hepatocellular cancers and lymphoma
2008-04-18 - Swiss Group for Clinical Cancer Research (SAKK) merged with the Swiss Institute of Applied Cancer Research (SIAK)
The structure of academic clinical cancer research in Switzerland is now more simplified
2008-04-17 - Evidence behind use of intensity-modulated radiotherapy
Latest from The Lancet Oncology
2008-04-16 - MEPs urged to act over hormonal chemicals that may cause breast cancer
Wake-up call for action to reduce people’s exposures to the chemicals that disrupt hormones and mimic estrogen
2008-04-15 - MammaPrint launched in France
The first prognostic test to evaluate individual risk of recurrence of breast cancer after surgery and to determine which women need chemotherapy
2008-04-14 - An Investigator’s View on Clinical Trials in Germany
No strict separation of clinical and scientific work, most studies are conducted at university-based hospitals
2008-04-11 - Scientists find genes coding for nicotinic receptor components and raising risk of lung cancer
Latest from Nature Genetics
2008-04-09 - Stopping a cancer trial early: is it for the benefit of patients or industry?
Patients could be harmed by new therapies being rushed prematurely into clinic
2008-04-09 - Increased Risk of Recurrence After Hormone Replacement Therapy in Breast Cancer Survivors
From the HABITS Study Group
2008-04-09 - Concept and Clinical Evaluation of Carrier-Mediated Anticancer Agents
Advances in the use of carrier vehicles delivering pharmacologic agents and enzymes to sites of disease
2008-04-07 - Challenges and Barriers to Academic Cancer Research
The Highlights from Slovenian EU Presidency Cancer Conference - The Burden of Cancer – How Can it be Reduced?
2008-04-04 - The Laboratory for Translational Research in Radio-oncology was admitted to ONCOTYROL, Center for Personalized Cancer Medicine
News from Medical University Center, Innsbruck, Austria
2008-04-03 - The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer
From the START Trialists' Group
2008-04-02 - Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy
Latest from Annals of Oncology
2008-04-01 - Belgium has set up a cancer plan
Made up of 32 measures and divided into three major areas: prevention, care, and research
2008-03-31 - EMEA recommends new contraindication for bortezomib
Benefits of bortezomib are greater than its risks, except in patients with acute diffuse infiltrative pulmonary and pericardial disease
2008-03-31 - EMEA extended indication for ibritumomab tiuxetan (Zevalin)
Now approved for consolidation therapy after remission induction in previously untreated patients with follicular lymphoma
2008-03-28 - VEGF Inhibition and Renal Thrombotic Microangiopathy
Glomerular injury in patients who are treated with bevacizumab is probably due to direct targeting of VEGF by antiangiogenic therapy
2008-03-27 - Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study
Latest from Lancet Oncology
2008-03-25 - Cetuximab-Induced Anaphylaxis
Latest from The New England Journal of Medicine
2008-03-25 - Benefits of letrozole following tamoxifen treatment for breast cancer patients
2008-03-18 - Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer
2008-03-14 - Safe Chemo
An EU-funded assessment of technology for validation of robotics and softwares in cytotoxics compounding
2008-03-13 - S-1, a novel oral fluorouracil antitumor drug in first-line treatment of advanced gastric cancer
Results of SPIRITS trial published in the latest issue of Lancet of Oncology
2008-03-12 - The challenge of biosimilars
Latest from Annals of Oncology, March 2008
2008-03-11 - Centralised preparation center for cytotoxic drugs in North Estonia Medical Center
New activity in Estonia
2008-03-10 - Physicians and pharmaceutical industry relationship in UK
The Royal College of Physicians identified a need to examine political, economic, commercial, organizational, professional, and public barriers to creating an ideal relationship
2008-03-07 - Management of bevacizumab-associated bowel perforation: a case series and review of the literature
Latest from Annals of Oncology, March 2008
2008-03-06 - The successor to European Commissioner for Health, Mr. Markos Kyprianou, is Mrs. Androula Vassiliou - Chairperson of the Board of Trustees of the Cyprus Oncology Centre
2008-03-05 - Searching Hematopoietic Stem Cell Donors
European Marrow Donor Information System (EMDIS) Defines Global Standard
2008-03-03 - Breast cancer: French Academy of Medicine backs chemoprevention for high risk women
Cancer therapy pioneer studied the reasons for the increasing incidence of invasive breast cancers in industrialized countries
2008-02-29 - Meeting highlights from the EMEA Committee for Medicinal Products for Human Use, 18-21 February 2008
Extended indication for pemetrexed
2008-02-27 - European Parliament voted to postpone for the implementation of the EU Directive on electromagnetic fields four years
Upon concern that Directive would have effectively banned the use of MRI for cancer diagnosis and cancer research
2008-02-26 - Assessing prognosis and optimizing treatment in patients with postchemotherapy viable NSGCT
Results of the surgical complete response - sCR2 international study
2008-02-25 - Genome-wide profiling of epigenetic therapy in cervical cancer
Presented at 19th International Congress on Anti-Cancer Treatment, 5-8 February, 2008, Paris, France
2008-02-22 - Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group
Still in pre-rituximab era
2008-02-21 - Report from the Genitourinary Cancers Symposium
14-16 February, 2008, San Francisco, USA
2008-02-20 - Structural Genomic Variation and Personalized Medicine
Clinical implications of basic research – The New England Journal of Medicine (February, 2008)
2008-02-19 - EMEA Statement on the safety of Gardasil
No causal relationship has been established between the deaths of two young European women and the administration of Gardasil
2008-02-18 - Lymphocyte-Predominant and Classical Hodgkin's Lymphoma
A Comprehensive Analysis From the German Hodgkin Study Group
2008-02-14 - Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck
Latest from Annals of Oncology, January 2008
2008-02-14 - WHO report on global tobacco control efforts
Only 5% of the global population is protected by comprehensive national smoke-free legislation and 40% of countries still allow smoking in hospitals and schools
2008-02-14 - European Action in the Field of Rare Diseases
European Medicines Agency Committee meeting for Orphan Medicinal Products
2008-02-07 - A new chapter begins for EORTC
The European Organization for Research and Treatment (EORTC) remains a matrix organization whose success will be directly linked to collaborations between the Scientific and the Methodology and Operations branches
2008-02-07 - News from European Medicines Agency Committee for Medicinal Products for Human Use meeting
Marketing authorization for cancer drugs with orphan designation
2008-02-07 - Incidence and risk of hypertension with sorafenib in patients with cancer
A systematic review and meta-analysis, Lancet Oncology, January 2008
2008-01-30 - The European Association of Hospital Pharmacists Guidance on Pharmacy Handling of Gene Medicines
Below the requirements for storage, transportation, dispensing, administration and disposal of all materials involved in handling of gene therapeutics
2008-01-29 - Does UGT1A1*28 homozygosity predict severe toxicity in patients treated with 5-fluorouracil -irinotecan?
Below the results of the PETACC 3-EORTC 40993-SAKK 60/00 trial in stage II-III colon cancer
2008-01-28 - News from Gastrointestinal Cancers Symposium
25-27 January, 2007, Orlando, USA
2008-01-21 - The effects of cancer treatment on reproductive functions
Guidance on management produced by the Royal College of Physicians, The Royal College of Radiologists and the Royal College of Obstetricians and Gynaecologists
2008-01-18 - "Westernizing" Women's Risks? Breast Cancer in Lower-Income Countries
Perspective published in the January issue of The New England Journal of Medicine
2008-01-15 - European Cervical Cancer Prevention Week, 20-26 January 2008
One million signatures to present a petition to the European Commissioner for Health
2008-01-11 - News from EMEA December 2007 meeting
Committee for Medicinal Products for Human Use - decisions on initial applications for cancer drugs marketing authorisation and extension of indications
2008-01-09 - News from San Antonio Breast Cancer Symposium
13-16 December, 2007, San Antonio, Texas, USA
2007-11-21 - Cancer immunology and immunotherapy: old problems, new directions
ESMO International Symposium on Immunology
2007-10-23 - Soft tissue sarcoma and GIST
ESMO-hosted consensus meeting
2007-07-08 - Hormone inhibitor promising for hard-to-treat prostate cancer
For prostate cancer patients whose tumors have continued to grow despite medical or surgical castration, a new drug candidate that inhibits production of male hormones anywhere in the body is showing promise in early trials.
2007-07-07 - Cancer-fighting virus shows promise in early clinical trial
A virus that has been specifically designed by scientists to be safe to normal tissue but deadly to cancer is showing early promise in a preliminary study, researchers said today at the ESMO Conference Lugano (ECLU), Switzerland.
2007-07-07 - Analysis confirms benefits of combining trastuzumab and chemotherapy
A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.
2006-10-02 - Adding hormone therapy to radiotherapy in prostate cancer increases progression-free survival
Patients with locally advanced prostate cancer who are treated with a combination of radiotherapy and hormonal therapy gain as much as 12% longer progression-free survival compared to those given radiotherapy alone.
2006-10-02 - Study shows value of EGFR mutations in predicting response to gefitinib in lung cancer
Lung cancer patients who have specific mutations in part of the gene for the cell surface molecule called epithelial growth factor receptor (EGFR) are much more likely to respond well to treatment with the drug gefitinib.
2006-10-02 - Mouthwash prevents oral sores and ulcers in chemotherapy patients
The painful mouth sores and ulcers that often trouble patients being treated with chemotherapy can be prevented either with ice chips or with an antiseptic mouthwash containing chlorhexidine. The antiseptic has the benefit of not being restricted to use with chemotherapy agents with a short half-life.
2006-10-02 - Cetuximab improves response to chemotherapy in metastatic colorectal cancer
Adding the cancer-targeting antibody cetuximab to normal cytotoxic chemotherapy for patients with advanced colorectal cancer improves efficacy and results in a better response rate, two groups of researchers report.
2006-10-02 - Easy-to-take regimen just as good for metastatic colorectal cancer
For patients with colorectal cancer that has spread to other parts of their body, an easy-to-take oral chemotherapy regimen is just as effective in terms of survival as another that includes a drug that must be administered via an intravenous line. The preliminary results of this Phase III study also show that adding the antibody bevacizumab (Avastin) to standard chemotherapy regimens offers significant improvements in progression-free survival.
2006-10-02 - Test may spot lung cancer patients who will respond to chemotherapy
Spanish researchers have shown that testing for the expression of a specific gene in tumour tissue can help predict which metastatic lung cancer patients will respond to chemotherapy. Their results, reported for the first time today at the 31st Congress of the European Society for Medical Oncology (ESMO), could one day help physicians identify patients who will better respond to the drug cisplatin--avoiding ineffective chemotherapy with its inherent side effects and expense.
2006-10-02 - Study offers clues about why some non-smokers get lung cancer
Researchers in France have identified a group of molecular markers that are distinct to some lung cancer patients who have never smoked. Their findings suggest the possibility that lung adenocarcinoma, currently the most common lung cancer, may be a "different" disease in molecular terms in smokers and non-smokers.
2006-10-02 - Drug combination offers benefits for postmenopausal women with HER2-positive metastatic breast cancer
Post-menopausal women whose metastatic breast cancer is positive for hormone receptors and HER2 can extend the time during which their disease does not progress if treated with a combination of trastuzumab (Herceptin) and anastrozole (Arimidex), compared to anastrozole alone.
2006-10-02 - Three-drugvcombination delays disease progression in metastatic breast cancer
For patients with HER2-postive metastatic breast cancer, the combination of trastuzumab, docetaxel and capecitabine seems to delay disease progression and increase progression free survival compared to trastuzumab and docetaxel only, according to Phase II results reported today at that 31st Congress of the European Society for Medical Oncology (ESMO) in Istanbul, Turkey.
2006-10-02 - Trials show dexrazoxane effective for serious anthracycline side-effect
Two multicenter studies have shown that the drug dexrazoxane can effectively treat accidental, anthracycline extravasation, a feared complication of chemotherapy which, if left untreated, can progress over weeks to devastating necrosis. Danish researchers report that only one out of 54 patients required surgical resection.
2006-10-02 - Blood test distinguishes between lung cancer and other lung diseases
Embargo date has been broken, therefore has been lifted!
2006-10-02 - Cetuximab dose escalation can benefit some metastatic colorectal patients
Some patients with metastatic colorectal cancer who do not experience the acne-like rash normally associated with cetuximab treatment may achieve better response rates if their dose is escalated, according to preliminary data report. The skin rash patients experience on cetuximab tends to correlate with how their cancer responds to the drug, which is an epidermal growth factor receptor (EGFR) inhibitor.
2006-10-01 - In lung cancer, cisplatin plus vinorelbine offers major survival benefits after lung resection
For lung cancer patients who have undergone a complete lung resection, treatment with a combination of the drugs cisplatin and vinorelbine offers a significant survival benefit, international researchers report.
2006-10-01 - Anthracycline-free chemotherapy shows promise in advanced breast cancer
For women with advanced breast cancer, three different chemotherapy regimens that avoid potentially cardio-toxic anthracycline drugs all offer benefits in terms of survival and disease progression.
2006-10-01 - Lapatinib effective for some women with inflammatory breast cancer
A new anti-cancer therapy that is easy to take and lacks most of the side-effects of conventional chemotherapy may be particularly effective for a sub-set of patients with the most lethal form of breast cancer
 
Login
Username
Password
Forgot password?
Enter your E-mail address
Contacts
Communication
media@esmo.org
Web-related questions
website@esmo.org